Table A1.
Details of main chemotherapy regimens used in the treatment of patients with MPNST. ADIC, doxorubicin + dacarbazine; AI, doxorubicin + ifosfamide; AP3, doxorubicin + cisplatin; EI, etoposide + ifosfamide; GEM, gemcitabine; GEM+DXL, gemcitabine + docetaxel; HD-IFO, high-dose ifosfamide.
| Regimen | Drug | Dose | Day (of 21-Day Cycle) |
|---|---|---|---|
| AI | Doxorubicin | 25 mg/m2 | 1–3 |
| Ifosfamide | 2.5 g/m2 | 1–4 | |
| ADIC | Doxorubicin | 15 mg/m2 | 1–5 |
| Dacarbazine | 150 mg/m2 | 1–5 | |
| AP3 | Doxorubicin | 20 mg/m2 | 1–3 |
| Cisplatin | 30 mg/m2 | 1–3 | |
| HD-IFO | Ifosfamide | 1.7 g/m2 | 1–7 |
| EI | Etoposide | 100 mg/m2 | 1–5 |
| Ifosfamide | 1.5 g/m2 | 1–5 | |
| GEM | Gemcytabine | 650 mg/m2 | 1, 8 |
| GEM+DXL | Gemcytabine | 650 mg/m2 | 1, 8 |
| Docetaxel | 50 mg/m2 | 8 | |
| Pazopanib | Pazopanib | 800 mg | daily |